Filing Flows › Taysha Gene Therapies (TSHA) › Q2 2025 › vs Q2 2024
Taysha Gene Therapies (TSHA) Q2 2025 vs Q2 2024 (year over year)
Taysha Gene Therapies's revenue rose $874K (+79%) from $1.1M in Q2 2024 to $2.0M in Q2 2025.
Taysha Gene Therapies, Q2 2025: revenue $2.0M (+79% year over year), net loss $26.9M, operating cash flow −$20.2M. The chart draws each line against Q2 2024, the increases inside each band.
Every line
| Line | Q2 2025 | Q2 2024 | Change | % |
|---|---|---|---|---|
| Revenue | $2.0M | $1.1M | $874K | +79% |
| Net loss | $26.9M | $20.9M | $6.0M | +28% |
| Costs & expenses | $28.9M | $22.4M | $6.5M | +29% |
| Operating costs | $28.7M | $22.4M | $6.3M | +28% |
| Interest & other, net | $129K | −$371K | $500K | — |
| Research & development | $20.1M | $15.1M | $5.1M | +34% |
| General & admin | $8.6M | $7.3M | $1.3M | +17% |
| Operating cash sources | $26.9M | $20.9M | $6.0M | +28% |
| Depreciation | $300K | $300K | $0 | 0% |
| Share-based compensation | $3.2M | $3.3M | −$142K | -4% |
| Working capital & other | $3.2M | −$4.2M | $7.4M | — |
| Cash used in operations | $20.2M | $21.5M | −$1.3M | -6% |
| Net loss absorbed | $26.9M | $20.9M | $6.0M | +28% |
Questions
How much did Taysha Gene Therapies's revenue grow year over year in Q2 2025?
Taysha Gene Therapies's revenue rose $874K (+79%) from $1.1M in Q2 2024 to $2.0M in Q2 2025.